Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Janssen Research & Development, LLC
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06750094CT.gov A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | — | Recruiting | — | — | — |
NCT06662786CT.gov A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | — | Recruiting | — | — | — |
NCT05253651CT.gov A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05193292CT.gov Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT03698461CT.gov Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab | — | Completed | — | — | — |
NCT00440310CT.gov Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases | — | Completed | — | — | — |
NCT00190515CT.gov A Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Levofolinic Acid (this asset) | Janssen Research & Development, LLC | P3 | B · 63 |
| Oxaliplatin | Peking University Cancer Hospital & Institute | P4 | BBB |
| Fluorouracilum | Rutgers, The State University of New Jersey | P4 | BBB |
| Ferric Carboxymaltose [Ferinject] | Nottingham University Hospitals NHS Trust | P4 | BBB |
| Irinotecan | Shanghai Zhongshan Hospital | P4 | BBB |
| Regorafenib | Sergey Orlov, MD | P4 | BB |
| Capecitabine | Rutgers, The State University of New Jersey | P4 | BB |
| Nivolumab | Bristol-Myers Squibb | P3 | BB |
| Vandazole | Helsinki University Central Hospital | P4 | BB |
+41 more in the Colorectal Neoplasm cohort
Other indications for Levofolinic Acid
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastroesophageal Junction Adenocarcinoma | — | P3 | BB · 68 |
| Colorectal Cancer | — | P3 | BB · 68 |
| Colon Adenocarcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Levofolinic Acid in Colorectal Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/levofolinic-acid-colorectal-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →